Literature DB >> 6163527

Methotrexate cytotoxicity in cultured human leukemic cells studied by flow cytometry.

I W Taylor, M H Tattersall.   

Abstract

Methotrexate (MTX)(2 x 10(-8) M) inhibited DNA synthesis in CCRF-CEM cells, causing cells to accumulate in early S phase while cellular RNA content and cell size continued to increase. Two-parameter flow cytometric analysis of DNA and RNA showed these cells to be unbalanced with excessive RNA relative to DNA content. Fifty % of cells remained viable after a 96-hr exposure to 2 x 10(-8) M MTX. In contrast, 10(-4) M MTX inhibited cell cycle progression of cells in both G1 and S phases and also prevented the development of unbalanced growth. In this instance, cell viability was reduced to 10% after 96 hr of drug exposure. The relative contribution of inhibition of thymidylate and purine biosynthesis to MTX cytotoxicity was investigated by addition of exogenous thymidine (10(-5) M) or hypoxanthine (10(-4) M). Thymidine reduced the cytotoxicity and inhibition of DNA synthesis caused by both doses of MTX and prevented classical unbalanced growth with 2 x 10(-8) m MTX; treatment with 10(-4) M MTX resulted in a form of unbalanced growth where cells had a relative excess of DNA compared with RNA content. The addition of hypoxanthine enhanced the classical unbalanced growth pattern seen with 2 x 10(-8) M MTX but was accompanied by a partial reduction of both the MTX-induced cytotoxicity and the inhibition of DNA synthesis (to an extent similar to that seen with exogenous thymidine). Potentiation of cell killing was observed with the addition of hypoxanthine to cells treated with 10(-4) M MTX. Complete rescue from MTX cytotoxicity at both concentrations was found only when both thymidine and hypoxanthine were present. These finding suggest that MTX cytotoxicity is associated with inhibition of DNA synthesis resulting from the disturbance of both thymidylate and purine biosynthesis.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6163527

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

Review 1.  Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. III. Antimetabolites, tubulin-binding agents, platinum drugs, amsacrine, L-asparaginase, interferons, steroids and other miscellaneous antitumor agents.

Authors:  A G Bosanquet
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  The effect of vinca alkaloids in enhancing the sensitivity of a methotrexate-resistant (L1210/R7A) line, studied by flow cytometric and chromosome number analysis.

Authors:  A T McGown; D G Poppitt; R Swindell; B W Fox
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

3.  Human mutations in methylenetetrahydrofolate dehydrogenase 1 impair nuclear de novo thymidylate biosynthesis.

Authors:  Martha S Field; Elena Kamynina; David Watkins; David S Rosenblatt; Patrick J Stover
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-29       Impact factor: 11.205

Review 4.  Biological and biochemical properties of new anticancer folate antagonists.

Authors:  D W Fry; R C Jackson
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

5.  Methotrexate released in vitro from bone cement inhibits human stem cell proliferation in S/G2 phase.

Authors:  Egon Prochazka; Tomas Soukup; Milos Hroch; Leos Fuksa; Eva Brcakova; Jolana Cermanova; Gabriela Kolouchova; Karel Urban; Jaroslav Mokry; Stanislav Micuda
Journal:  Int Orthop       Date:  2009-02-11       Impact factor: 3.075

6.  Methotrexate induces differentiation of human keratinocytes.

Authors:  P M Schwartz; S K Barnett; E S Atillasoy; L M Milstone
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-15       Impact factor: 11.205

7.  Treatment of the rat R-1 rhabdomyosarcoma with methotrexate and radiation; effects of timing on cell survival and tumour growth delay.

Authors:  J B Kipp; H B Kal; A H van Gennip; A H van Berkel
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

8.  Enhanced cytotoxicity with methotrexate in conjunction with hypoxanthine in L1210 cells in culture.

Authors:  C R Fairchild; J Maybaum; J A Straw
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

9.  Stimulation of dihydrofolate reductase promoter activity by antimetabolic drugs.

Authors:  H B Eastman; A G Swick; M C Schmitt; J C Azizkhan
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

10.  DNA fragmentation, dATP pool elevation and potentiation of antifolate cytotoxicity in L1210 cells by hypoxanthine.

Authors:  J B Kwok; M H Tattersall
Journal:  Br J Cancer       Date:  1992-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.